 | • レポートコード：MRC2-11QY11255 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はカルチノイド症候群管理のグローバル市場について調査・分析したレポートです。種類別（化学療法、生物学的療法、肝動脈塞栓剤）市場規模、用途別（病院、クリニック、がん研究所、治療センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別カルチノイド症候群管理の競争状況、市場シェア ・世界のカルチノイド症候群管理市場：種類別市場規模 2015年-2020年（化学療法、生物学的療法、肝動脈塞栓剤） ・世界のカルチノイド症候群管理市場：種類別市場規模予測 2021年-2026年（化学療法、生物学的療法、肝動脈塞栓剤） ・世界のカルチノイド症候群管理市場：用途別市場規模 2015年-2020年（病院、クリニック、がん研究所、治療センター） ・世界のカルチノイド症候群管理市場：用途別市場規模予測 2021年-2026年（病院、クリニック、がん研究所、治療センター） ・北米のカルチノイド症候群管理市場分析：米国、カナダ ・ヨーロッパのカルチノイド症候群管理市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのカルチノイド症候群管理市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のカルチノイド症候群管理市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのカルチノイド症候群管理市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Novartis、Omega Laboratories、Teva Pharmaceutical、Mylan、Ipsen Biopharmaceuticals、Sirtex Medical、BTG International、Wockhardt、Sun Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor.
The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Market Analysis and Insights: Global Carcinoid Syndrome Management Market
The global Carcinoid Syndrome Management market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Carcinoid Syndrome Management Scope and Market Size
Carcinoid Syndrome Management market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Carcinoid Syndrome Management market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Novartis
Omega Laboratories
Teva Pharmaceutical
Mylan
Ipsen Biopharmaceuticals
Sirtex Medical
BTG International
Wockhardt
Sun Pharmaceutical
Market segment by Type, the product can be split into
Chemotherapy
Biological Therapy
Hepatic Artery Embolization Agents
Market segment by Application, split into
Hospitals
Clinics
Cancer Institute and Treatment Centers
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Carcinoid Syndrome Management Revenue
1.4 Market by Type
1.4.1 Global Carcinoid Syndrome Management Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Biological Therapy
1.4.4 Hepatic Artery Embolization Agents
1.5 Market by Application
1.5.1 Global Carcinoid Syndrome Management Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Cancer Institute and Treatment Centers
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Carcinoid Syndrome Management Market Perspective (2015-2026)
2.2 Global Carcinoid Syndrome Management Growth Trends by Regions
2.2.1 Carcinoid Syndrome Management Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Carcinoid Syndrome Management Historic Market Share by Regions (2015-2020)
2.2.3 Carcinoid Syndrome Management Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Carcinoid Syndrome Management Market Growth Strategy
2.3.6 Primary Interviews with Key Carcinoid Syndrome Management Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Carcinoid Syndrome Management Players by Market Size
3.1.1 Global Top Carcinoid Syndrome Management Players by Revenue (2015-2020)
3.1.2 Global Carcinoid Syndrome Management Revenue Market Share by Players (2015-2020)
3.1.3 Global Carcinoid Syndrome Management Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Carcinoid Syndrome Management Market Concentration Ratio
3.2.1 Global Carcinoid Syndrome Management Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Carcinoid Syndrome Management Revenue in 2019
3.3 Carcinoid Syndrome Management Key Players Head office and Area Served
3.4 Key Players Carcinoid Syndrome Management Product Solution and Service
3.5 Date of Enter into Carcinoid Syndrome Management Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Carcinoid Syndrome Management Historic Market Size by Type (2015-2020)
4.2 Global Carcinoid Syndrome Management Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Carcinoid Syndrome Management Market Size by Application (2015-2020)
5.2 Global Carcinoid Syndrome Management Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Carcinoid Syndrome Management Market Size (2015-2020)
6.2 Carcinoid Syndrome Management Key Players in North America (2019-2020)
6.3 North America Carcinoid Syndrome Management Market Size by Type (2015-2020)
6.4 North America Carcinoid Syndrome Management Market Size by Application (2015-2020)
7 Europe
7.1 Europe Carcinoid Syndrome Management Market Size (2015-2020)
7.2 Carcinoid Syndrome Management Key Players in Europe (2019-2020)
7.3 Europe Carcinoid Syndrome Management Market Size by Type (2015-2020)
7.4 Europe Carcinoid Syndrome Management Market Size by Application (2015-2020)
8 China
8.1 China Carcinoid Syndrome Management Market Size (2015-2020)
8.2 Carcinoid Syndrome Management Key Players in China (2019-2020)
8.3 China Carcinoid Syndrome Management Market Size by Type (2015-2020)
8.4 China Carcinoid Syndrome Management Market Size by Application (2015-2020)
9 Japan
9.1 Japan Carcinoid Syndrome Management Market Size (2015-2020)
9.2 Carcinoid Syndrome Management Key Players in Japan (2019-2020)
9.3 Japan Carcinoid Syndrome Management Market Size by Type (2015-2020)
9.4 Japan Carcinoid Syndrome Management Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Carcinoid Syndrome Management Market Size (2015-2020)
10.2 Carcinoid Syndrome Management Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Carcinoid Syndrome Management Market Size by Type (2015-2020)
10.4 Southeast Asia Carcinoid Syndrome Management Market Size by Application (2015-2020)
11 India
11.1 India Carcinoid Syndrome Management Market Size (2015-2020)
11.2 Carcinoid Syndrome Management Key Players in India (2019-2020)
11.3 India Carcinoid Syndrome Management Market Size by Type (2015-2020)
11.4 India Carcinoid Syndrome Management Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Carcinoid Syndrome Management Market Size (2015-2020)
12.2 Carcinoid Syndrome Management Key Players in Central & South America (2019-2020)
12.3 Central & South America Carcinoid Syndrome Management Market Size by Type (2015-2020)
12.4 Central & South America Carcinoid Syndrome Management Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Novartis
13.1.1 Novartis Company Details
13.1.2 Novartis Business Overview
13.1.3 Novartis Carcinoid Syndrome Management Introduction
13.1.4 Novartis Revenue in Carcinoid Syndrome Management Business (2015-2020))
13.1.5 Novartis Recent Development
13.2 Omega Laboratories
13.2.1 Omega Laboratories Company Details
13.2.2 Omega Laboratories Business Overview
13.2.3 Omega Laboratories Carcinoid Syndrome Management Introduction
13.2.4 Omega Laboratories Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.2.5 Omega Laboratories Recent Development
13.3 Teva Pharmaceutical
13.3.1 Teva Pharmaceutical Company Details
13.3.2 Teva Pharmaceutical Business Overview
13.3.3 Teva Pharmaceutical Carcinoid Syndrome Management Introduction
13.3.4 Teva Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.3.5 Teva Pharmaceutical Recent Development
13.4 Mylan
13.4.1 Mylan Company Details
13.4.2 Mylan Business Overview
13.4.3 Mylan Carcinoid Syndrome Management Introduction
13.4.4 Mylan Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.4.5 Mylan Recent Development
13.5 Ipsen Biopharmaceuticals
13.5.1 Ipsen Biopharmaceuticals Company Details
13.5.2 Ipsen Biopharmaceuticals Business Overview
13.5.3 Ipsen Biopharmaceuticals Carcinoid Syndrome Management Introduction
13.5.4 Ipsen Biopharmaceuticals Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.5.5 Ipsen Biopharmaceuticals Recent Development
13.6 Sirtex Medical
13.6.1 Sirtex Medical Company Details
13.6.2 Sirtex Medical Business Overview
13.6.3 Sirtex Medical Carcinoid Syndrome Management Introduction
13.6.4 Sirtex Medical Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.6.5 Sirtex Medical Recent Development
13.7 BTG International
13.7.1 BTG International Company Details
13.7.2 BTG International Business Overview
13.7.3 BTG International Carcinoid Syndrome Management Introduction
13.7.4 BTG International Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.7.5 BTG International Recent Development
13.8 Wockhardt
13.8.1 Wockhardt Company Details
13.8.2 Wockhardt Business Overview
13.8.3 Wockhardt Carcinoid Syndrome Management Introduction
13.8.4 Wockhardt Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.8.5 Wockhardt Recent Development
13.9 Sun Pharmaceutical
13.9.1 Sun Pharmaceutical Company Details
13.9.2 Sun Pharmaceutical Business Overview
13.9.3 Sun Pharmaceutical Carcinoid Syndrome Management Introduction
13.9.4 Sun Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2015-2020)
13.9.5 Sun Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Carcinoid Syndrome Management Key Market Segments
Table 2. Key Players Covered: Ranking by Carcinoid Syndrome Management Revenue
Table 3. Ranking of Global Top Carcinoid Syndrome Management Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Carcinoid Syndrome Management Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Biological Therapy
Table 7. Key Players of Hepatic Artery Embolization Agents
Table 8. Global Carcinoid Syndrome Management Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Carcinoid Syndrome Management Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Carcinoid Syndrome Management Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Carcinoid Syndrome Management Market Share by Regions (2015-2020)
Table 12. Global Carcinoid Syndrome Management Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Carcinoid Syndrome Management Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Carcinoid Syndrome Management Market Growth Strategy
Table 18. Main Points Interviewed from Key Carcinoid Syndrome Management Players
Table 19. Global Carcinoid Syndrome Management Revenue by Players (2015-2020) (Million US$)
Table 20. Global Carcinoid Syndrome Management Market Share by Players (2015-2020)
Table 21. Global Top Carcinoid Syndrome Management Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Carcinoid Syndrome Management as of 2019)
Table 22. Global Carcinoid Syndrome Management by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Carcinoid Syndrome Management Product Solution and Service
Table 25. Date of Enter into Carcinoid Syndrome Management Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 28. Global Carcinoid Syndrome Management Market Size Share by Type (2015-2020)
Table 29. Global Carcinoid Syndrome Management Revenue Market Share by Type (2021-2026)
Table 30. Global Carcinoid Syndrome Management Market Size Share by Application (2015-2020)
Table 31. Global Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 32. Global Carcinoid Syndrome Management Market Size Share by Application (2021-2026)
Table 33. North America Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 35. North America Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 36. North America Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 37. North America Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 38. North America Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 39. Europe Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 41. Europe Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 43. Europe Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 45. China Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 46. China Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 47. China Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 48. China Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 49. China Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 50. China Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 51. Japan Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 53. Japan Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 55. Japan Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 59. Southeast Asia Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 61. Southeast Asia Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 63. India Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 64. India Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 65. India Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 66. India Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 67. India Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 68. India Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Carcinoid Syndrome Management Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Carcinoid Syndrome Management Market Share (2019-2020)
Table 71. Central & South America Carcinoid Syndrome Management Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Carcinoid Syndrome Management Market Share by Type (2015-2020)
Table 73. Central & South America Carcinoid Syndrome Management Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Carcinoid Syndrome Management Market Share by Application (2015-2020)
Table 75. Novartis Company Details
Table 76. Novartis Business Overview
Table 77. Novartis Product
Table 78. Novartis Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 79. Novartis Recent Development
Table 80. Omega Laboratories Company Details
Table 81. Omega Laboratories Business Overview
Table 82. Omega Laboratories Product
Table 83. Omega Laboratories Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 84. Omega Laboratories Recent Development
Table 85. Teva Pharmaceutical Company Details
Table 86. Teva Pharmaceutical Business Overview
Table 87. Teva Pharmaceutical Product
Table 88. Teva Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 89. Teva Pharmaceutical Recent Development
Table 90. Mylan Company Details
Table 91. Mylan Business Overview
Table 92. Mylan Product
Table 93. Mylan Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 94. Mylan Recent Development
Table 95. Ipsen Biopharmaceuticals Company Details
Table 96. Ipsen Biopharmaceuticals Business Overview
Table 97. Ipsen Biopharmaceuticals Product
Table 98. Ipsen Biopharmaceuticals Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 99. Ipsen Biopharmaceuticals Recent Development
Table 100. Sirtex Medical Company Details
Table 101. Sirtex Medical Business Overview
Table 102. Sirtex Medical Product
Table 103. Sirtex Medical Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 104. Sirtex Medical Recent Development
Table 105. BTG International Company Details
Table 106. BTG International Business Overview
Table 107. BTG International Product
Table 108. BTG International Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 109. BTG International Recent Development
Table 110. Wockhardt Business Overview
Table 111. Wockhardt Product
Table 112. Wockhardt Company Details
Table 113. Wockhardt Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 114. Wockhardt Recent Development
Table 115. Sun Pharmaceutical Company Details
Table 116. Sun Pharmaceutical Business Overview
Table 117. Sun Pharmaceutical Product
Table 118. Sun Pharmaceutical Revenue in Carcinoid Syndrome Management Business (2015-2020) (Million US$)
Table 119. Sun Pharmaceutical Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Carcinoid Syndrome Management Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Biological Therapy Features
Figure 4. Hepatic Artery Embolization Agents Features
Figure 5. Global Carcinoid Syndrome Management Market Share by Application: 2020 VS 2026
Figure 6. Hospitals Case Studies
Figure 7. Clinics Case Studies
Figure 8. Cancer Institute and Treatment Centers Case Studies
Figure 9. Carcinoid Syndrome Management Report Years Considered
Figure 10. Global Carcinoid Syndrome Management Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Carcinoid Syndrome Management Market Share by Regions: 2020 VS 2026
Figure 12. Global Carcinoid Syndrome Management Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Carcinoid Syndrome Management Market Share by Players in 2019
Figure 15. Global Top Carcinoid Syndrome Management Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Carcinoid Syndrome Management as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Carcinoid Syndrome Management Revenue in 2019
Figure 17. North America Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Carcinoid Syndrome Management Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
カルチノイド症候群下痢治療の世界市場（～2026年） Carcinoid syndrome is a group of symptoms that can occur in patients suffering from carcinoid tumors which also called as metastatic neuroendocrine tumors. Carcinoid tumors are rare and these are slow growing tumors. Most of the tumors occur in gastrointestinal tract. According to FDA, carcinoid syn…- 化学療法薬誘発性肢端紅斑（手足症候群）治療の世界市場（～2026年） Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear afte…
- アスペルガー症候群治療の世界市場（～2026年） The Asperger syndrome is a type of developmental disorders known as Autistic Spectrum Disorder (ASD). These disorders initiate in childhood and stay with individuals until their adult life. Children with the Asperger syndrome function better than those with autism, and they have normal intelligence …
- 多嚢胞性卵巣症候群治療の世界市場（～2026年） Polycystic ovary syndrome is a set of symptoms due to elevated androgens in females. Signs and symptoms of polycystic ovary syndrome nclude irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant and patches of thick, darker, velv…
- 腫瘍随伴症候群治療の世界市場（～2026年） A paraneoplastic syndrome is a rare group of disorder that is triggered by an abnormal immune system response caused by the neoplasm. This syndrome mostly occurs when cancer-fighting antibodies mistakenly attack normal cells in the nervous system. The prevalence of this disorder can be typically see…